REDWOOD CITY, Calif., July 10, 2018 -- Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the appointment, effective immediately, of Jaafer Golzar, MD, as the Company's Chief Medical Officer. Dr. Golzar provides Avinger with an extensive and impressive history of clinical leadership within the endovascular field.
Dr. Golzar is a practicing interventional cardiologist with Advocate Medical Group in Chicago. He is the Director of Limb Salvage and Endovascular Intervention at Advocate Trinity Hospital. Dr. Golzar is also a leading educator on interventional techniques and technologies and is the founder and previous director of the Chicago Endovascular Conference (CVC), an international-scale annual conference designed to address the educational needs of physicians and other health care professionals treating patients with peripheral arterial and venous diseases. Prior to joining Avinger, Dr. Golzar was also Medical Director – Interventional Vascular for BTG International. He has participated in multiple clinical research trials, including studies of PAD treatment with atherectomy, drug-eluting balloons and stents and has authored numerous publications in peer-reviewed journals. As a recognized leader in the endovascular community, Dr. Golzar has received multiple accolades including the prestigious Pioneers in Performance - North America Award in 2014. He is a Fellow of the American College of Cardiology and of the Society for Cardiovascular Angiography and Interventions. Dr. Golzar will maintain a part-time clinical practice while he serves as Avinger's Chief Medical Officer.
Story Continues Below Advertisement
Ad Statistics
Times Displayed: 2556
Times Visited: 21
Get financing today. We say YES more! Easy, Fast, Application. Pick the payment that best works for you. Tax Benefits + Leasing = Huge Savings! NEVER BE OBSOLETE. NO DOWN PAYMENT. FIXED MONTHLY PAYMENT. MRI, CT, Ultrasound, Digital X-ray, Dental Equipment

"We are extremely pleased that Dr. Golzar has joined our executive leadership team and are confident he will provide valuable clinical and strategic perspective to our company," said Jeff Soinski, president and CEO of Avinger. "His feedback on earlier versions of Avinger's Lumivascular technology led to many of the enhancements designed into our recently-launched next-generation Pantheris, and we anticipate his clinical acumen will contribute substantially to Avinger's future product development and clinical study initiatives. Furthermore, Dr. Golzar's relationships and respect within the PAD treatment community and among potential strategic partners will meaningfully and positively impact the adoption of Lumivascular and the value of our Company."